Review Article |
Featured
-
-
Comment |
The devotion to surrogate outcomes in drug development for liver disease
Surrogate end points are often used in clinical trials where the time to clinical outcomes is long. In patients with liver disease, these surrogate outcomes are rarely validated. Without validation, treatment effects reported in trials might not directly translate to patient benefit after licensing.
- Ian A. Rowe
-
-
-